Sentences with phrase «drug price regulations»

Spicer's comments during a press briefing predictably put a damper on biotech stocks — but it wasn't nearly the plunge the Trump administration's other statements about drug price regulations have wrought.

Saunders has openly argued that pharma can head off more stringent drug price regulation in the U.S. (such as Trump's suggestions of competitive bidding and direct negotiations in Medicare) by self - policing.

Pharma and biotech stocks swooned recently (the S&P Pharmaceuticals Select Industry Index is down 25 % in the last three months), largely on concerns about greater drug price regulation.

A more leftist system of greater drug price regulation could come with other negative side - effects, Miller continued.

Not exact matches

And within a span of six weeks this fall, Hillary Clinton caused a drop in biotech stocks with a tweet calling for greater regulation of drug prices, then single - handedly tanked stocks of private - corrections companies when she tweeted about prison reform.

He's endorsed policies like direct drug price negotiation in Medicare (usually a Democratic wish list item that's despised by drug makers) while simultaneously promising to slash other regulations on the biopharma industry; he famously promised «insurance for everybody» yet ostensibly supports benefit cuts and a rollback of the Medicaid expansion, which has covered millions of the poorest Americans.

Concerns that a Hillary Clinton administration would impose greater price regulation on drug companies had put a damper on pharmaceutical stocks for more than a year.

Investors have, on balance, concluded that the combination of a shift to very expansionary fiscal policy and major reductions in regulation in sectors ranging from energy to finance to drug pricing will raise demand and reflate the American economy.

The market selloff in biotech began last year when Hilary Clinton commented on drug price gouging and the need for increased regulation.

Investments in fast - growing industries like the technology and healthcare sectors (which have historically been volatile) could result in increased price fluctuation, especially over the short term, due to the rapid pace of product change and development and changes in government regulation of companies emphasizing scientific or technological advancement or regulatory approval for new drugs and medical instruments.

Investments in fast - growing industries like the technology and health care sectors (which have historically been volatile) could result in increased price fluctuation, especially over the short term, due to the rapid pace of product change and development and changes in government regulation of companies emphasizing scientific or technological advancement or regulatory approval for new drugs and medical instruments.

Theoretically, better regulation of drugs pricing might increase the cost efficiency of the health system, without changing other aspects.

A five - year deal, the pharmaceutical price regulation scheme (PPRS), was agreed in 2005, allowing drugs companies to set their own prices inside maximum profit allowances.

«These provisions could threaten everything from Buy America contracting provisions to New York State's ban on hydro - fracking and setting discounted prices for vital prescription drugs to regulations to protect consumer from noxious financial industry practices,» they wrote.

Too - strict regulations might limit patient access to the drug by driving prices up, said Julie Netherland, deputy state director of the Drug Policy Alliadrug by driving prices up, said Julie Netherland, deputy state director of the Drug Policy AlliaDrug Policy Alliance.

The Patent Act and the PM (NOC) Regulations seek to balance «effective patent enforcement» over new and innovative drugs with the «timely market entry» of lower priced generic versions once the patents have expired.

Derek Lowe writes at In the Pipeline that Novartis and Roche are so displeased with the government's approach to drug pricing and regulations on clinical trials that they are threatening to pull their R&D out of the country.

[11] In order to stop this inflationary effect on generic drug prices, in 2006, the Ontario Drug Benefit Act, the Drug Interchangeability and Dispensing Fee Act, and the Regulations under them were amended to prohibit rebadrug prices, in 2006, the Ontario Drug Benefit Act, the Drug Interchangeability and Dispensing Fee Act, and the Regulations under them were amended to prohibit rebaDrug Benefit Act, the Drug Interchangeability and Dispensing Fee Act, and the Regulations under them were amended to prohibit rebaDrug Interchangeability and Dispensing Fee Act, and the Regulations under them were amended to prohibit rebates.

[10] Prior to 2006, the price at which manufacturers could apply to list generic drugs in the Formulary was capped by regulations under the Actsat effectively 63 % of the price of the brand - name drug.

Life science companies are preparing themselves for continued regulatory uncertainty during 2017, as drug pricing remains a hot - button issue and regulations evolve to meet new healthcare reforms.

Stocking and pricing of medications in inventory ensuring availability of drugs by delivering them to patients or facilities maintaining pharmacy's (and its patients» employees») safety by adhering to infection - control procedures, policies and regulations compounding intravenous (iv) solutions delivering medications to and from satellite pharmacies restocking automated medication dispensing systems mixing and dispensing orally - administered medications unit - dosing tablets from a bulk bottle must have a acpe certification and cpr certification.